Company intelligence / Profile preview

ProGnosis Biotech

Ownership: Private
Development stage: Other

Overview

ProGnosis Biotech develops and manufactures validated immunodiagnostic tests—primarily ELISA kits and lateral flow assays—for rapid detection of infectious diseases in clinical settings as well as contaminants/pathogens in food/feed/agriculture. Their products are exported to over 85 countries, with regulatory certifications including ISO9001. No traditional "clinical trial" pipeline exists; their products undergo validation against international standards.

Therapeutic areas: Infectious Diseases
Modalities: ELISA-based immunoassaysLateral Flow AssaysAntibody-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

No major pharma/biopharma partnerships disclosedCollaborates with global distributorsParticipates in proficiency testing programs with agencies such as BIPEA/FAPAS/ILVO/ISO-certified bodies

Beyond the preview

Go deeper on ProGnosis Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProGnosis Biotech.

Explore the full profile